Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 19/20 | 0.46 |
| ▸ | UGCG | Q16739 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16933646 | 0.96 | NTMT1 (0.46) | NTMT1UGCGPPARDPPARA | |
| SCHEMBL16933476 | 0.94 | NTMT1 (0.49) | NTMT1UGCG | |
| SCHEMBL16933647 | 0.90 | NTMT1 (0.49) | NTMT1UGCGPPARDPPARA | |
| SCHEMBL16933578 | 0.78 | HRH3 (0.38) | — | |
| SCHEMBL16007828 | 0.78 | NTMT1 (0.59) | NTMT1UGCG | |
| SCHEMBL16007827 | 0.78 | NTMT1 (0.59) | NTMT1UGCG | |
| SCHEMBL29386898 | 0.77 | NTMT1 (0.72) | NTMT1UGCG | |
| Hydrochloric Acid SCHEMBL17504473 | 0.77 | NTMT1 (0.58) | NTMT1UGCG | |
| SCHEMBL16933479 | 0.77 | CHRM5 (0.40) | — | |
| SCHEMBL16933481 | 0.77 | CHRM5 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895484-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 795/4885UGCG 4/4885PPARD 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.